Triplett D A, Banez E I, Harms C S
Thromb Res. 1983 Sep 15;31(6):855-62. doi: 10.1016/0049-3848(83)90116-0.
The fluorogenic substrate assay of antithrombin III (AT III) was compared with a thrombin inhibition (two-stage) clotting test and a radial immunodiffusion assay. Normal ranges based on a population of 25 individuals were 88-121% (fluorogenic substrate), 72-111% (clotting) and 22.5-35.3 mg/dl (RID). A clinical comparison of the methods showed a linear relationship between the fluorogenic substrate and immunologic methods (r = 0.69, p less than 0.005), as well as between the fluorogenic substrate and clotting methods (r = 0.75, p less than 0.005). The fluorogenic substrate assay reflected the highest incidence of low AT III levels in all three clinical groups included (36 patients with arteriosclerosis, 18 with fractures and 37 with thrombosis/embolism).
将抗凝血酶III（AT III）的荧光底物检测法与凝血酶抑制（两阶段）凝血试验及放射免疫扩散试验进行了比较。基于25名个体的正常范围为88 - 121%（荧光底物法）、72 - 111%（凝血法）和22.5 - 35.3mg/dl（放射免疫扩散法）。这些方法的临床比较显示，荧光底物法与免疫学法之间呈线性关系（r = 0.69，p < 0.005），荧光底物法与凝血法之间也呈线性关系（r = 0.75，p < 0.005）。在纳入的所有三个临床组（36例动脉硬化患者、18例骨折患者和37例血栓形成/栓塞患者）中，荧光底物检测法显示低AT III水平的发生率最高。
